Behandlung des postoperativen Hypoparathyreoidismus

Zusammenfassung

Hypokalzämien treten nach Operationen an der Schilddrüse oder Nebenschilddrüse relativ häufig auf. Sie sind bei etwa drei Viertel der Fälle nur transient und es kommt zu einer spontanen Normalisierung innerhalb weniger Tage. In einem kleinen Teil der Fälle (1 – 6 %) resultiert jedoch ein permanenter postoperativer Hypoparathyreoidismus mit lebenslanger Substitutionspflicht für Kalzium, aktive Vitamin D-Präparate oder Parathormon jeweils allein oder in Kombination. Langzeitfolgen eines schlecht behandelten Hypoparathyreoidismus betreffen mehrere Organsysteme und beinhalten auch intrazerebrale Verkalkungen, eine Nephrosklerose und eine verminderte Lebensqualität.

Abstract

Hypocalcaemia is quite common after surgery of the thyroid gland or the parathyroid glands. In about three quarters of the cases it‘s only transient and spontaneous normalisation occurs within a few days. In 1 – 6 % postsurgical hypoparathyroidism persists with the need of lifelong follow-up and treatment with calcium, active Vitamine D and parathyroid hormone, alone or in combination. Longterm sequelae of a poorly controlled hypoparathyroidism affect different organ systems including intracerebral calcifications and nephrosclerosis and may result in reduced quality of life.

Schlüsselwörter

Hypoparathyreoidismus - Postoperativ - Parathormon - Therapie

Keywords

Hypoparathyroidism - Postsurgical - Parathyroid hormone - Treatment

Publication History

Article published online:
21 September 2020

• Literatur

• 1 Clarke BL, Brown EM, Collins MT. et al. Epidemiology and Diagnosis of Hypoparathyroidism. The Journal of Clinical Endocrinology and Metabolism 2016; 101: 2284-2299
• 2 Bartsch DK, Dotzenrath C, Vorländer C. et al. The StuDo QTSGTSS. Current Practice of Surgery for Benign Goitre-An Analysis of the Prospective DGAV StuDoQ|Thyroid Registry. Journal of Clinical Medicine 2019; 8: 477 DOI: 10.3390/jcm8040477.
• 3 Goltzman D. Physiology of Parathyroid Hormone. Endocrinology and Metabolism Clinics of North America 2018; 47: 743-758
• 4 Maurer E, Maschuw K, Reuss A. et al. Total Versus Near-total Thyroidectomy in Graves Disease: Results of the Randomized Controlled Multicenter TONIG-trial. Annals of Surgery 2019; 270: 755-761
• 5 Kazaure HS, Sosa JA. Surgical Hypoparathyroidism. Endocrinology and Metabolism Clinics of North America 2018; 47: 783-796
• 6 Kazaure HS, Zambeli-Ljepovic A, Oyekunle T. et al. Severe Hypocalcemia After Thyroidectomy: An Analysis of 7366 Patients. Annals of Surgery 2019; DOI: 10.1097/sla.0000000000003725. Online ahead of print
• 7 Eismontas V, Slepavicius A, Janusonis V. et al. Predictors of postoperative hypocalcemia occurring after a total thyroidectomy: results of prospective multicenter study. BMC surgery 2018; 18: 55-55
• 8 Underbjerg L, Sikjaer T, Mosekilde L. et al. Cardiovascular and renal complications to postsurgical hypoparathyroidism: a Danish nationwide controlled historic follow-up study. J Bone Miner Res 2013; 28: 2277-2285
• 9 Astor MC, Løvås K, Debowska A. et al. Epidemiology and Health-Related Quality of Life in Hypoparathyroidism in Norway. The Journal of Clinical Endocrinology and Metabolism 2016; 101: 3045-3053
• 10 Siggelkow H, Clarke BL, Germak J. et al. Burden of illness in not adequately controlled chronic hypoparathyroidism: Findings from a 13-country patient and caregiver survey. Clinical Endocrinology 2020; 92: 159-168
• 11 Mitchell DM, Regan S, Cooley MR. et al. Long-term follow-up of patients with hypoparathyroidism. The Journal of Clinical Endocrinology and Metabolism 2012; 97: 4507-4514
• 12 Fahr T. Idiopathische Verkalkung der Hirngefäße. Zentralblatt für Allgemeine Pathologie und Pathologische Anatomie 1930; 50: 129-133
• 13 Sakane EN, Vieira MCC, Lazaretti-Castro M. et al. Predictors of Poor Bone Microarchitecture Assessed by Trabecular Bone Score in Postsurgical Hypoparathyroidism. The Journal of Clinical Endocrinology and Metabolism 2019; 104: 5795-5803
• 14 Payne RB, Little AJ, Williams RB. et al. Interpretation of serum calcium in patients with abnormal serum proteins. British Medical Journal 1973; 4: 643-646
• 15 Khan AA, Koch C, Van Uum SHM. et al. Standards of Care for Hypoparathyroidism in Adults. European Journal of Endocrinology 2018; 180: 1-22
• 16 Schäffler A. Hormone replacement after thyroid and parathyroid surgery. Dtsch Arztebl Int 2010; 107: 827-834
• 17 Mannstadt M, Clarke BL, Vokes T. et al. Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study. The Lancet Diabetes & Endocrinology 2013; 1: 275-283
• 18 Mannstadt M, Clarke BL, Bilezikian JP. et al. Safety and Efficacy of 5 Years of Treatment With Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism. The Journal of Clinical Endocrinology and Metabolism 2019; 104: 5136-5147
• 19 Vokes TJ, Mannstadt M, Levine MA. et al. Recombinant Human Parathyroid Hormone Effect on Health-Related Quality of Life in Adults With Chronic Hypoparathyroidism. The Journal of Clinical Endocrinology and Metabolism 2018; 103: 722-731
• 20 Tay YD, Tabacco G, Cusano NE. et al. Therapy of Hypoparathyroidism With rhPTH(1-84): A Prospective, 8-Year Investigation of Efficacy and Safety. The Journal of Clinical Endocrinology and Metabolism 2019; 104: 5601-5610